Literature DB >> 5314809

[Clinical investigation of intermediate- and high-purity antihaemophilic factor (factor VIII) concentrates].

A J Johnson, M H Karpatkin, J Newman.   

Abstract

Mesh:

Substances:

Year:  1971        PMID: 5314809     DOI: 10.1111/j.1365-2141.1971.tb03414.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

1.  An alternative method of large scale plasma fractionation for the isolation of serum albumin.

Authors:  W Schneider; H Lefévre; H Fiedler; L J McCarty
Journal:  Blut       Date:  1975-02

2.  Report of a clinical trial of a Canadian preparation of antihemophilic factor.

Authors:  A A Magnin; S E Johnson
Journal:  Can Med Assoc J       Date:  1979-08-18       Impact factor: 8.262

3.  Multi-channel preparation of fresh blood an economic therapy with blood components.

Authors:  W Schneider; K Glassner; C Fröhlich; L J McCarty
Journal:  Blut       Date:  1974-02

4.  Moynihan Lecture, 1980. Major surgery in haemophilia.

Authors:  W J Rudowski
Journal:  Ann R Coll Surg Engl       Date:  1981-03       Impact factor: 1.891

5.  Short PEG-linkers improve the performance of targeted, activatable monoclonal antibody-indocyanine green optical imaging probes.

Authors:  Kohei Sano; Takahito Nakajima; Kiminori Miyazaki; Yuya Ohuchi; Takashi Ikegami; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2013-05-03       Impact factor: 4.774

Review 6.  Clinical pharmacokinetics of factor VIII in patients with classic haemophilia.

Authors:  A Messori; G Longo; M Matucci; M Morfini; P L Ferrini
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

Review 7.  NIR fluorescence-guided tumor surgery: new strategies for the use of indocyanine green.

Authors:  Claire Egloff-Juras; Lina Bezdetnaya; Gilles Dolivet; Henri-Pierre Lassalle
Journal:  Int J Nanomedicine       Date:  2019-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.